First Mature Estimation of Median OS for Selpercatinib in Patients with RET Fusion-Positive NSCLC By Ogkologos - March 12, 2025 822 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from final efficacy and safety analyses from the LIBRETTO-001 study Source RELATED ARTICLESMORE FROM AUTHOR Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength MOST POPULAR Lo que deben saber las personas con cáncer de mama y... January 4, 2024 Comprehensive Genomic Profiling with Molecularly-Guided Therapy Results in Longer PFS Compared... August 26, 2024 Oncology Research Rebounds from Pandemic Low, but Shows Cancer Patients Need... September 10, 2021 Long-Term Efficacy of Single-Agent Neoadjuvant/Adjuvant PD1 Blockade for Resectable Cutaneous Melanoma... August 16, 2023 Load more HOT NEWS Why consistent and funded cancer policies are key to improving cancer... The ‘major conditions strategy’: will ministers fail to give cancer the... Indicators of Outcome Are Identified for Nivolumab Treatment of Patients with... Studies Test CAR T-Cell Therapies Designed to Overcome Key Limitations
